RGLS 4326
Alternative Names: RGLS-4326Latest Information Update: 01 Jul 2025
At a glance
- Originator Regulus Therapeutics
- Developer Novartis
- Class Antisense oligonucleotides; MicroRNAs
- Mechanism of Action MIRN17 microRNA inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autosomal dominant polycystic kidney disease
Most Recent Events
- 25 Jun 2025 Regulus Therapeutics has been acquired and merged into Novartis
- 07 Nov 2024 Pharmacodynamics data from a preclinical trial in Autosomal dominant polycystic kidney disease released by Regulus Therapeutics
- 12 Nov 2021 Regulus Therapeutics completes a phase I trial in Autosomal dominant polycystic kidney disease (In adults, In the elderly) in USA (SC) (NCT04536688)